about
Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysisBiochemical and Structural Characterization of Lysophosphatidic Acid Binding by a Humanized Monoclonal AntibodyAngiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysisMolecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeuticsSystematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis.Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma.Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis.Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in KoreaA phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancerAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Targeted therapies in renal cell cancer: recent developments in imagingThe anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.Sunitinib and other targeted therapies for renal cell carcinoma.Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccineFKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells.Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal productAntiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical responseSunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms.Expression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapyPotential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancerInduction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cellsA novel p21 attenuator which is structurally related to sorafenib.PtdIns-4,5-P2 as a potential therapeutic target for pathologic angiogenesis.Prognostic biomarkers in renal cell carcinoma.Molecular therapy in urologic oncology.Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinomaImatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer.Angiogenesis-related pathways in the pathogenesis of ovarian cancer
P2860
Q26746200-B44575A1-627F-49A1-BD51-3D238E8DC0F0Q27667249-25BC610F-A740-49DA-A1D1-87299A9C4D72Q28534015-39725299-5673-4947-9D1A-4B68C3141D41Q28544659-32812ADF-FF63-4CA3-997A-6916A88673EDQ30319002-8406B0ED-013B-4E2C-9C72-D459CEEA0F46Q33379941-CD1D53AC-78C4-4207-9A7A-2F49337D9C83Q33384772-9DEBC2CD-73B0-4C34-9E0C-E812BA62241BQ33418378-DD65D9BE-C271-4535-B246-C72C68E7C5B2Q33490826-3B926973-CCE6-4133-9007-AD0A3830A2ECQ33576205-5D70549B-1CF1-47A8-B945-53375EA16D8EQ33652589-D904F7CB-C199-42C5-A20D-7FF7B5F053ECQ33733303-D548E4E9-5359-4B80-9F92-88756EB8252DQ33781661-9B3E2C2C-8376-4B9F-8A44-20834BC08A0AQ33869431-0AEE5178-E387-400F-AE06-04C44FEC4E9AQ33931392-5B8EFCFA-EBED-442F-B60E-CF6F3BAA7919Q34023737-B1330090-F96E-4BD1-810D-B65F0EACB12CQ34088265-54515376-3515-4A53-B89A-AE60DA02727AQ34088696-09727F32-06E8-4A36-88B6-38425AF62F80Q34606294-950213DA-07EB-4A4F-9F50-8D56B769C7F9Q34621802-051F82EA-B3E5-49AC-AD7A-C6334F0DBF53Q34627828-C426B50F-7097-4088-BF73-7C8FBC5A09D8Q34675774-C7010D61-EB2B-445D-BBBB-2383CF226BF8Q34688048-DFB20602-8E11-46E2-9F62-4C8D464948BCQ34948760-7E6BB863-5571-4EAF-91D8-78B5A14D2BD2Q35033957-B1CED098-5DC2-4073-B4DD-A72A065C3625Q35057295-C3069256-55A3-4546-B05B-5441024F09B0Q35109141-595B1CBB-980F-4275-B4FA-320D6173CEA9Q35584920-EDB58926-401A-40A9-B440-31AFA643C9A4Q35854397-19AE3F3B-EA57-4CE3-B698-B55B71684F6DQ36216688-8361F52D-2B3F-4169-BECE-47DA351A45E3Q36429759-267EFECB-E3D9-420C-9EA4-8B36B09AD677Q36622608-FF80FA9F-4D28-4F70-88EA-2BA89167BFABQ36677729-09353BBC-D7B4-4A0D-BED1-43BB535ACF99Q36764870-3412F02C-CCD8-433D-BD7B-CF731735060FQ36816038-375CBC0D-F748-465D-BDD4-EDB96923E4EBQ36878961-C516895D-306C-42A7-BF4A-1138A8EE863BQ37014111-2E037D18-43F5-45F0-A346-DDD8E750E105Q37052897-5321FF2D-3363-4898-8BCB-2EDD6F8591B9Q37137002-A8289399-FB6F-4540-9F13-5D7BE4716185Q37139109-88002D3E-BE59-447B-8D24-3FA7892AD384
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeted therapy for metastatic renal cell carcinoma.
@ast
Targeted therapy for metastatic renal cell carcinoma.
@en
Targeted therapy for metastatic renal cell carcinoma.
@nl
type
label
Targeted therapy for metastatic renal cell carcinoma.
@ast
Targeted therapy for metastatic renal cell carcinoma.
@en
Targeted therapy for metastatic renal cell carcinoma.
@nl
prefLabel
Targeted therapy for metastatic renal cell carcinoma.
@ast
Targeted therapy for metastatic renal cell carcinoma.
@en
Targeted therapy for metastatic renal cell carcinoma.
@nl
P356
P1476
Targeted therapy for metastatic renal cell carcinoma.
@en
P2093
Ronald M Bukowski
P304
P356
10.1200/JCO.2006.08.5415
P407
P577
2006-12-01T00:00:00Z